What triggered NuCana shares' latest price pullback

Traders Union
All News
Financial News
Nucana slides 2.15% today to $1.82

Highlights

NuCana will report earnings before market open on March 19, with investor focus on updates from its proprietary ProTide cancer therapy platform.
No additional corporate events or new fundamental catalysts have been reported ahead of earnings, keeping attention on pipeline progress and results.
Shares trade in a persistent downtrend well below key technical resistance, with strong negative momentum and high probability of further declines into the $1.73–$1.77 range.

Earnings anticipation heightened as product platform draws attention

NuCana is scheduled to announce its earnings results before the market opens on Thursday, March 19th. The company utilizes its proprietary ProTide platform to develop enhanced nucleoside analogues for improving chemotherapy efficacy and safety in solid tumor treatments. No further company-specific events were reported.

Anton Kharitonov, expert at Traders Union, notes severe technical weakness in NuCana plc ADR. The price remains entrenched below all major moving averages, signaling little hope for a near-term reversal. He highlights persistent seller control across intraday and longer timeframes. Recent price action reflects low demand and failed attempts at support retention. "Until buyers reclaim lost levels, NCNA is likely to make new lows and should be avoided for now," Kharitonov cautions.

Viktoras Karapetjanc, expert at Traders Union, views the upcoming earnings release as a catalyst that could shift sentiment. He believes the proprietary ProTide platform remains a strategic strength for NuCana. Karapetjanc sees potential for renewed investor interest once fundamental results provide clarity. "The underlying biotech innovation positions NCNA for upside, and any positive earnings surprise could spark a strong recovery move," he affirms.

Jainam Mehta, market strategist, sees NCNA trading in a compressed range with oversold signals flashing. While prevailing momentum is negative, he watches for tactical reversals if the support at $1.73 holds. Mehta considers the subdued volatility an invitation for short-term setups. "A contrarian entry may develop if sentiment turns and price rejects further downside in coming sessions," Mehta suggests.

Bearish momentum prevails as sellers maintain control on all signals

NCNA trades well below the MA-20 at $2.06, MA-50 at $2.56, and MA-200 at $5.92, highlighting strong seller pressure across all timeframes. The nearest dynamic resistance is at $2.08 (Ichimoku Kijun), with sellers controlling the short-, medium-, and long-term trends. Momentum indicators are firmly negative, with MACD pointing to a strong sell and ADX at 30.15 signaling seller dominance, though weekly ADX hints at possible trend strength. Oscillators reflect oversold conditions: RSI at 34.26, CCI deeply negative, and Stoch RSI near oversold zones. BBP indicates sellers drive intraday momentum, while AO neutrality does not counter the downtrend. The price is trading down 2.15% on the day, opening just $0.01 below the prior close (no meaningful gap). With the current price at $1.82 sitting at the lower end of today’s $1.82 – $1.89 range, volatility has been low, and pressure has persisted after the open. Most momentum and oscillator signals are aligned, affirming a negative intraday bias.

Previously it was reported that NuCana shares were under sustained technical pressure, with bearish momentum dominating across all timeframes. The latest analysis not only reaffirms this negative trend but also highlights that a break below $1.73 could signal a move to fresh lows, making this support level crucial for traders to monitor in the coming sessions.

Source of Data: NCNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.